Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.891
Peer-review started: December 9, 2023
First decision: December 14, 2023
Revised: January 1, 2024
Accepted: January 23, 2024
Article in press: January 23, 2024
Published online: February 16, 2024
Processing time: 53 Days and 2.4 Hours
Inflammatory bowel disease (IBD), mainly consisted of Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease. As a vital antioxidant, urate can decrease oxidative stress in vivo, which may be associated with IBD state. However, the causality between IBD and urate levels has not been investigated.
Previous studies indicated uric acid-to-creatinine ratio and urate were positively correlated with the disease activity of CD and UC. Despite the existing findings demonstrated the bidirectional associations between urate levels and IBD, including UC and CD, the causality association between them remains unclear. This study seeks to investigate the causal association between IBD and urate through Mendelian randomization (MR) study, which may shed crucial new insight into treating and preventing IBD. In specific, IBD patients may benefit from monitoring and reducing serum urate levels.
The study aims to investigate the bidirectional causal relationship between urate levels and IBD by performing MR analysis, to better understand the gene susceptibility of urate levels and IBD.
Single nucleotide polymorphisms retrieved from genome-wide association studies (GWASs) was selected as instrument variants. Summary GWAS statistics for instrument-outcome associations were retrieved from three separate databases for IBD (UK Biobank, FinnGen database and a large GWAS meta-analysis) and one for urate levels (a large GWAS meta-analysis). Inverse-variance-weighted was performed to investigate the bidirectional causal relationship, and other sensitivity analysis were conducted to strengthen the results. Meta-analysis was conducted to merge the data from separate outcome databases using a fixed-effects model.
The current study found that the genetic susceptibility to urate levels was associated with increased UC risk [odds ratio (OR): 1.95, 95% confidence interval (CI): 1.86-2.05], and animal studies confirmed the positive association between urate levels and UC. Additionally, genetically predicted IBD was inversely related to urate levels (OR: 0.97, 95%CI: 0.94-0.99). However, no association was observed between genetically influenced UC or CD and urate levels.
This study identified urate levels might be risk factors for UC, whereas genetically predicted IBD was inversely associated with urate levels. The current results shed new insight into prevention and treatment of IBD.
Although the current study investigated the causal relationship between urate levels and UC, which was further verified by animal studies, the precise mechanism by which high urate levels affects the development of UC remains unknown. More basic and clinical studies should be conducted for identification of key regulators and molecules during the process.